TY - JOUR
T1 - Glucagon-like Peptide-1 and the Central/Peripheral Nervous System
T2 - Crosstalk in Diabetes
AU - Muscogiuri, Giovanna
AU - DeFronzo, Ralph A.
AU - Gastaldelli, Amalia
AU - Holst, Jens J.
N1 - Publisher Copyright:
© 2016 Elsevier Ltd
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Glucagon-like peptide-1 (GLP-1) is released in response to meals and exerts important roles in the maintenance of normal glucose homeostasis. GLP-1 is also important in the regulation of neurologic and cognitive functions. These actions are mediated via neurons in the nucleus of the solitary tract that project to multiple regions expressing GLP-1 receptors (GLP-1Rs). Treatment with GLP-1R agonists (GLP-1-RAs) reduces ischemia-induced hyperactivity, oxidative stress, neuronal damage and apoptosis, cerebral infarct volume, and neurologic damage, after cerebral ischemia, in experimental models. Ongoing human trials report a neuroprotective effect of GLP-1-RAs in Alzheimer's and Parkinson's disease. In this review, we discuss the role of GLP-1 and GLP-1-RAs in the nervous system with focus on GLP-1 actions on appetite regulation, glucose homeostasis, and neuroprotection.
AB - Glucagon-like peptide-1 (GLP-1) is released in response to meals and exerts important roles in the maintenance of normal glucose homeostasis. GLP-1 is also important in the regulation of neurologic and cognitive functions. These actions are mediated via neurons in the nucleus of the solitary tract that project to multiple regions expressing GLP-1 receptors (GLP-1Rs). Treatment with GLP-1R agonists (GLP-1-RAs) reduces ischemia-induced hyperactivity, oxidative stress, neuronal damage and apoptosis, cerebral infarct volume, and neurologic damage, after cerebral ischemia, in experimental models. Ongoing human trials report a neuroprotective effect of GLP-1-RAs in Alzheimer's and Parkinson's disease. In this review, we discuss the role of GLP-1 and GLP-1-RAs in the nervous system with focus on GLP-1 actions on appetite regulation, glucose homeostasis, and neuroprotection.
KW - appetite
KW - central nervous system
KW - glucagon-like peptide-1
KW - neurodegenerative diseases
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85006048214&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006048214&partnerID=8YFLogxK
U2 - 10.1016/j.tem.2016.10.001
DO - 10.1016/j.tem.2016.10.001
M3 - Review article
C2 - 27871675
AN - SCOPUS:85006048214
SN - 1043-2760
VL - 28
SP - 88
EP - 103
JO - Trends in Endocrinology and Metabolism
JF - Trends in Endocrinology and Metabolism
IS - 2
ER -